About APAC Biotech
APAC Biotech is a Healthcare company based in Gurugram (India) founded in 2010. Autologous monocyte-derived dendritic cell immunotherapy for cancer is developed. APAC Biotech has raised $991.24 thousand across 1 funding round from investors including Projects Development. APAC Biotech was last valued at $4.03 million in March 2011. Its chief executive, as recorded, is Arun Mehra. Its Indian entity Apac Biotech Private Limited reported revenue of ₹1.99 Cr. APAC Biotech offers products and services including APCEDEN® and LTR-Memvaxraleucel™. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
APAC Biotech was founded in 2010 in Gurugram, India, within the biotechnology sector. Focus is placed on developing autologous monocyte-derived dendritic cell immunotherapy for various cancers. The primary therapy, Apceden, employs patients own monocytes to target cancer-specific dendritic cells. Treatments have been established for colorectal cancer, non-small cell lung carcinoma, ovarian carcinoma, and prostate cancer. Ongoing development targets glioblastoma multiforme and renal cancer.
- Headquarters Gurugram, India
- Stage Minicorn
- SectorsHealthcare
- Website apacbiotech.com
- Social LinkedIn X Facebook
- Legal Name Apac Biotech Private Limited
- Date of Incorporation 21 Dec, 2010
- Jurisdiction Delhi, India
- Annual Revenue₹1.99 Cr
FY 2024 · +72% YoY
- Net Loss-₹56.6 Lakh
FY 2024 · -28% margin
- EBITDA₹4 Lakh
FY 2024 · 2% margin
- Total Equity Funding$991.24K (USD)
in 1 rounds
- Latest Funding Round$991.24K (USD), Seed
Mar 2011
- Investors
Associated legal entities of APAC Biotech
APAC Biotech operates through Apac Biotech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Apac Biotech Private Limited CIN U85110DL2010PTC211616 | Active | 21 Dec 2010 | New Delhi, Delhi | ₹2.0 Cr | 6 | View details |
Products & Services of APAC Biotech
APAC Biotech offers a comprehensive portfolio of products and services, including APCEDEN® and LTR-Memvaxraleucel™.
Personalized dendritic cell therapy to enhance immune response against cancer.
Reprograms immune cells to treat cancer like a viral infection.
Funding Insights of APAC Biotech
APAC Biotech has successfully raised a total of $991.24K through 1 strategic funding round. The most recent funding activity was a Seed round of $991.24 thousand completed in March 2011. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $991,237
- Total Rounds 1
- Last Round Seed — $991,237
- First Round $991,237
(Mar 2011)
- Investors Count 1
All 1 funding rounds of APAC Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2011 | $991,237 | Seed | $4.03M | Projects Development | – |
| Date | Valuation | Stage |
|---|---|---|
| Mar 2011 | $4.03M | •••••••• |
Last known valuation $4.03M (Mar 2011). 1 investors in total: 1 institutional.
Investors in APAC Biotech
APAC Biotech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Projects Development.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Develops residential and commercial projects with innovative designs in Lebanon. | 2002 | projectsdevelopment.com | Beirut, Lebanon |
Investor details for APAC Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Apac Biotech Private Limited (APAC Biotech)
Apac Biotech Private Limited is the primary company behind APAC Biotech. The board of Apac Biotech Private Limited currently have 6 directors; the longest-serving is Sanjiv Kumar Jain, appointed in 2010. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sanjiv Kumar Jain DIN 02725843 | Director | 21 Dec 2010 | 15 yrs 10 mo | Apac Biotech Private Limited |
| Arun Mehra DIN 00241888 | Managing Director | 21 Dec 2010 | 15 yrs 10 mo | Apac Biotech Private Limited |
| Anita Mehra DIN 02176148 | Director | 11 Jan 2011 | 15 yrs 9 mo | Apac Biotech Private Limited |
| Anju Sanjiv Kumar Jain DIN 02732637 | Director | 24 Jan 2011 | 15 yrs 9 mo | Apac Biotech Private Limited |
| Bandana Sharan DIN 03471527 | Director | 01 Apr 2011 | 15 yrs 7 mo | Apac Biotech Private Limited |
| Atika Mehra DIN 03604350 | Director | 01 Feb 2024 | 2 yrs 8 mo | Apac Biotech Private Limited |
People of APAC Biotech
1 people are tracked at APAC Biotech (1 in leadership).
| Name | Role | Group |
|---|---|---|
| CEO & MD | Leadership |
Complete people profiles for APAC Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of APAC Biotech
Figures of Apac Biotech Private Limited, the primary company behind APAC Biotech, for FY 2024. Revenue was ₹1.99 Cr (+72% year on year). Net loss was -₹56.6 Lakh (-28% margin). EBITDA was ₹4 Lakh (2% margin). Revenue has grown at a compounded annual rate of +19% over three years and -6% over five years.
- ₹1.99 CrRevenue · FY 2024 · +72% YoY
- -₹56.6 LakhNet loss · -28% margin
- ₹4 LakhEBITDA · 2% margin
- ₹36 LakhPaid-up capital
- +19%Revenue CAGR, 3 years
- -6%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Apac Biotech Private Limited are on its company page.
Detailed financial statements for APAC Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of APAC Biotech
3 dated milestones of APAC Biotech across 1 years, from founding to its latest funding, stage changes and deals.
- Founded APAC Biotech is founded.
- Funding First funding round of $991K.
- Milestone Reaches Minicorn status.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Apac Biotech
Complete news archive for APAC Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about APAC Biotech
APAC Biotech was founded in 2010 and raised its 1st funding round 1 year after it was founded.
APAC Biotech is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
Arun Mehra is the CEO of APAC Biotech, as recorded in our data.
APAC Biotech is a funded company, having raised a total of $991.24K across 1 funding round to date. The company's 1st funding round was a Seed of $991.24K, raised on Mar 2011.
The primary company behind APAC Biotech, Apac Biotech Private Limited, reported revenue of ₹1.99 Cr for FY 2024, up 72% year on year.
APAC Biotech was founded in 2010 in Gurugram, India, within the biotechnology sector. Focus is placed on developing autologous monocyte-derived dendritic cell immunotherapy for various cancers. The primary therapy, Apceden, employs patients own monocytes to target cancer-specific dendritic cells. Treatments have been established for colorectal cancer, non-small cell lung carcinoma, ovarian carcinoma, and prostate cancer. Ongoing development targets glioblastoma multiforme and renal cancer.
APAC Biotech offers APCEDEN® and LTR-Memvaxraleucel™.
APAC Biotech has 1 investor. Key investors include Projects Development.
The valuation of APAC Biotech is $4.03M as of Mar 2011.
APAC Biotech operates through Apac Biotech Private Limited.
The legal entities of APAC Biotech currently have 6 directors, including Atika Mehra, Anita Mehra, Bandana Sharan and others.